financetom
Business
financetom
/
Business
/
IndusInd Bank's deputy CEO Arun Khurana resigns amid accounting blunder
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IndusInd Bank's deputy CEO Arun Khurana resigns amid accounting blunder
May 25, 2025 8:12 PM

MUMBAI/BENGALURU April 28 (Reuters) -

India's IndusInd Bank on Monday announced the

resignation of deputy CEO Arun Khurana, weeks after the private

lender disclosed

accounting lapses

in its derivatives portfolio that triggered a rout in its

shares

.

In light of the recent

accounting issues related to internal derivative trades

, "I having oversight of the Treasury Front office function,

as the whole time director, Deputy CEO and a part of senior

management of the bank, hereby resign, effective immediately,"

Khurana wrote in a letter to IndusInd Bank's board that was

included in a stock market filing.

IndusInd, India's fifth-largest private lender with a

balance sheet of $63 billion,

said on Sunday

it would take a $229.56 million hit to its accounts for the

financial year ended March 31, 2025 because of the incorrect

treatment of derivatives going back several years.

Based on the findings of an external agency's probe,

IndusInd has estimated an impact of 2.27% on its net worth as of

December 2024.

Khurana headed the global markets division of the bank,

which included the derivatives portfolio.

IndusInd shares have fallen nearly 8% since March 10,

when the lender first disclosed the impact on its net worth from

the discrepancies.

Last week, IndusInd named Santosh Kumar as its deputy

CFO. Kumar will head the finance and accounts functions till

IndusInd appoints a full-time CFO.

The Reserve Bank of India had

urged

CEO Sumant Kathpalia and Khurana to step down following the

accounting lapses, as soon as replacements were found and

approved by the central bank, Reuters reported last month.

The bank is due to report earnings for the full

financial year before May 15, but is yet to disclose the date

for the release.

(Reporting by Siddhi Nayak in Mumbai and Ananta Agarwal in

Bengaluru; Editing by Anil D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved